Navigation Links
Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZeneca's SEROQUEL(R) XR
Date:7/31/2008

FREMONT, Calif., July 31 /PRNewswire/ -- Handa Pharmaceuticals, LLC ("Handa"), a specialty pharmaceutical company based in Fremont, California, today confirmed that its Abbreviated New Drug Application ("ANDA") for Quetiapine Fumarate Extended-Release Tablets, the generic version of AstraZeneca's SEROQUEL(R) XR, has been accepted for filing by the U.S. Food and Drug Administration ("FDA"). Based upon available information, Handa believes that it is the first applicant to file an ANDA for SEROQUEL(R) XR containing a Paragraph IV certification, under the provisions of the Hatch- Waxman Act. Should its ANDA be approved by the FDA, Handa believes that its product will be entitled to 180 days of generic market exclusivity.

About Handa Pharmaceuticals, LLC

Handa Pharmaceuticals, LLC is a specialty pharmaceutical company that was established in the San Francisco Bay area in November 2005. Handa's executive leadership has a proven track record of developing controlled-release prescription pharmaceutical products that are difficult to formulate. For more information, please visit http://www.handapharma.com.

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Handa's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Handa disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Handa's current expectations depending upon a number of factors affecting Handa's business. These factors include, among others, patents and other intellectual property rights held by competitors and other third parties and the uncertainty of the outcome of litigation related to such patents and intellectual property rights; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the impact of competitive products and pricing; market acceptance of and demand for Handa's products; difficulties or delays in manufacturing; and other risks and uncertainties.

SEROQUEL(R) and SEROQUEL(R) XR are registered trademarks of the AstraZeneca group of companies.

Contact: Stephen Cary of Handa Pharmaceuticals, LLC, +1-510-354-2888


'/>"/>
SOURCE Handa Pharmaceuticals, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
2. Trubion Pharmaceuticals Provides Announcement Dates for Second Quarter and First Six Months Earnings Conference Call
3. DoctorDirectory to Co-market VoSpire ER(R) with DAVA Pharmaceuticals, Inc.
4. Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
5. Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP
6. New Natural Product from Zurich Pharmaceuticals Downs Appetite
7. AUDIO from Medialink and Duramed Pharmaceuticals: Not Your Mothers Menopause
8. Genesis Pharmaceuticals Announces New Board Member and Forms Committees
9. Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product
10. AUDIO from Medialink and Duramed Pharmaceuticals: Relief for Women Experiencing Surgical Menopause
11. Genesis Pharmaceuticals Announces SFDA Approval for Radix Isatidis Dispersible Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... OSF Ventures, the corporate ... largest start-up platform headquartered in Silicon Valley that connects startups to corporations and ... signed a three-year agreement to be a corporate sponsor of Plug and Play’s ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... from 140 Buzzies users who entered metrics into the product’s app. The ... The new data showed that within just 30 seconds of using Buzzies, people ...
(Date:1/23/2017)... ... 2017 , ... A Northwestern Pennsylvania addiction treatment center unveiled ... Rehabilitation & Recovery Center’s new website can be found at AlpineSpringsRehab.com . ... and retooled website. The treatment center has also revamped its social media strategy, ...
(Date:1/23/2017)... ... 2017 , ... DMG Productions is proud to announce the ... to broadcast Saturday, January 28, 2017 at 5:00pmEST. , This segment will educate ... the limitations of fatigue monitoring technologies within the mining industry. Today SmartCap is ...
(Date:1/23/2017)... OR (PRWEB) , ... January 23, 2017 , ... Sharon ... to the air to educate listeners about the benefits of making new water infrastructure ... U.S.,” Kleyne said, “it’s appropriate that we expect water infrastructure to become a top ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... January 23, 2017 ArisGlobal, a ... sciences, announces agClinical 3.3, the latest version of its ... life science organizations to confidently and efficiently meet new ... manage the electronic trial master file so that compliance ... ...
(Date:1/23/2017)... , Jan. 23, 2017  Therabron Therapeutics, ... a new standard in respiratory care, today announced ... Orphan Medicinal Products has granted Orphan Drug Designation ... of Bronchiolitis Obliterans Syndrome (BOS).  "We ... from the EMA to treat patients diagnosed with ...
(Date:1/23/2017)... , Jan. 23, 2017 MouthWatch LLC announced today ... was ranked as the best intraoral camera on DentalCompare,s list ... #2 spot overall. The #1 product was the CollaPlug ... MouthWatch intraoral camera was "…incredibly popular because it is by ... has a small sticker price, it doesn,t sacrifice quality imaging." ...
Breaking Medicine Technology: